Vyant Bio Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vyant Bio Inc had its IPO on 2013-04-05 under the ticker symbol VYNT.
The company operates in the Healthcare sector and Biotechnology industry. Vyant Bio Inc has a staff strength of 4 employees.
Shares of Vyant Bio Inc opened at $0.16 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.16 - $0.2, and closed at $0.16.
This is a -0.45% slip from the previous day's closing price.
A total volume of 69,786 shares were traded at the close of the day’s session.
In the last one week, shares of Vyant Bio Inc have slipped by -5.88%.
Vyant Bio Inc's Key Ratios
Vyant Bio Inc has a market cap of $980956, indicating a price to book ratio of 0.4142 and a price to sales ratio of 5.5207.
In the last 12-months Vyant Bio Inc’s revenue was $397000 with a gross profit of $-699000 and an EBITDA of $-13282000. The EBITDA ratio measures Vyant Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vyant Bio Inc’s operating margin was -3445.84% while its return on assets stood at -51.76% with a return of equity of -122.41%.
In Q4, Vyant Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 27.9%.
Vyant Bio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vyant Bio Inc’s profitability.
Vyant Bio Inc stock is trading at a EV to sales ratio of 0.3888 and a EV to EBITDA ratio of 0.0866. Its price to sales ratio in the trailing 12-months stood at 5.5207.
Vyant Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.21 million
- Total Liabilities
- $3.67 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Vyant Bio Inc ended 2023 with $15.21 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.21 million while shareholder equity stood at $9.91 million.
Vyant Bio Inc ended 2023 with $0 in deferred long-term liabilities, $3.67 million in other current liabilities, 1000.00 in common stock, $-101503000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.04 million and cash and short-term investments were $10.04 million. The company’s total short-term debt was $565,000 while long-term debt stood at $57000.00.
Vyant Bio Inc’s total current assets stands at $11.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $323000.00 compared to accounts payable of $655000.00 and inventory worth $53000.00.
In 2023, Vyant Bio Inc's operating cash flow was $0 while its capital expenditure stood at $9000.
Comparatively, Vyant Bio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vyant Bio Inc stock is currently trading at $0.16 per share. It touched a 52-week high of $3.7 and a 52-week low of $3.7. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $0.2 and 200-day moving average was $0.53 The short ratio stood at 1.8 indicating a short percent outstanding of 0%.
Around 1877.5% of the company’s stock are held by insiders while 448.6% are held by institutions.
Frequently Asked Questions About Vyant Bio Inc
Similar Industry Stocks (Biotechnology)
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD). The company is based in Cherry Hill, New Jersey.